Australian clinical-stage biotechnology company Vaxxas has expanded its global intellectual property portfolio to 42 patents, supporting its exclusive claim to manufacture and sell its proprietary vaccination technology, the HD-MAP, in the US, Europe, Asia and Australia. …
Vaxxas expands global IP portfolio for exclusive manufacture and sale of needle-free vaccination technology
November 27, 2024 Australian Biotech
Latest Video
New Stories
-
MSD to bring vaccine distribution back in-house after 40-year partnership
December 1, 2025 - - Latest News -
New PBS listing offers fresh hope for Australians living with debilitating skin condition
December 1, 2025 - - Latest News -
Five Australians honoured for leadership and community advocacy in evolving HIV response
December 1, 2025 - - Latest News -
Budget discipline tightens with agencies directed to target 'lowest priority work'
November 30, 2025 - - Latest News -
The 'Dispatched' Podcast - 30 November
November 30, 2025 - - Podcast -
Chimeric signals board refresh and shareholder support as lead trial advances
November 30, 2025 - - Australian Biotech -
Pharmac announces 90-day dispensed quantities of HIV medicines
November 27, 2025 - - Latest News